Journal: Osteoarthritis and Cartilage Open
Article Title: Interleukin-6 receptor blockade improves bone healing following ischemic osteonecrosis in adolescent mice
doi: 10.1016/j.ocarto.2023.100386
Figure Lengend Snippet: The assessment of VEGF expression at 2 weeks post-surgery in vivo and under hypoxic chondrocyte culture in vitro . (A) VEGF immunohistochemistry (IHC) showed increased VEGF expression in the areas of revascularization in the necrotic epiphysis (EP) of the MR-16 group at 2 weeks compared to the saline group. VEGF expression was also increased in the articular cartilage (AC) of the MR16-1 group while it was unchanged in the growth plate cartilage (GP). Scale bar; 20 μm . (B) Human chondrocytes were pretreated with tocilizumab (1 μg/ml, 10 μg/ml) for 1 h, followed by IL1-β exposure under normoxia (20% oxygen) or hypoxia (1% oxygen) for 16 h. Expression levels of VEGF were significantly increased with tocilizumab pretreatment. The value of the non-treatment group (i.e., no treatment under normoxia) was set as 1.0. Kruskal-Wallis test followed by Mann-Whitney U test was used among 3 conditions with IL-1 treatment under hypoxia (IL-1, IL-1+1 μg/ml tocilizumab, and IL-1+10 μg/ml tocilizumab). Values were expressed by the mean ± SD. Note that relative VEGF expression levels in hypoxia were higher compared to those in normoxia. ∗∗ p < 0.01.
Article Snippet: Primary chondrocytes were isolated from human articular cartilage (IRB protocol Study ID: STU012011-114) [ ] and were pretreated with tocilizumab, a humanized anti-interleukin-6 receptor antibody as an analog of MR16-1, at either 1 μg/ml or 10 μg/ml concentration for 1 h, followed by interleukin-1β (recombinant human IL1-β; 12.5 ng/ml, R&D systems, Minneapolis, MN, USA) treatment to stimulate IL-6 [ ] under normoxia (20% oxygen) or hypoxia (1% oxygen) for 16 h.
Techniques: Expressing, In Vivo, In Vitro, Immunohistochemistry, Saline, MANN-WHITNEY
Sino Biological is a verified supplier 
Sino Biological manufactures this product 
